TY - JOUR
T1 - The relation of sarcopenia and disability in multiple sclerosis
AU - Haider, Lukas
AU - Chung, Karen K.
AU - Mangesius, Stephanie
AU - Furtner, Julia
AU - Ciccarelli, Olga
AU - Chard, Declan T.
AU - Barkhof, Frederik
N1 - Funding Information: This study was funded by the MS Society of Great Britain and Northern Ireland [20; 984] Funding Information: DC is a consultant Hoffmann-La Roche. In the last three years he has been a consultant for Biogen, has received research funding from Hoffmann-La Roche, the International Progressive MS Alliance, the MS Society, and the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre, and a speaker's honorarium from Novartis. He co-supervises a clinical fellowship at the National Hospital for Neurology and Neurosurgery, London, which is supported by Merck.We are indebted to Professor David Miller and the late Professor W Ian McDonald for the inception and follow-up of this cohort. We thank all who participated in this study and all involved in data collection over the years. We thank Marios Yiannakas for undertaking the MRI scanning at 30-years; Drs Sean Morrissey, Jonathan O'Riordan, Peter A Brex and Leonora Fisniku, who undertook earlier follow-up of this cohort; and the MS Society for their sustained funding of this work. This study was funded by the MS Society of Great Britain and Northern Ireland [20; 984], This study was supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. LH was supported by an ECTRIMS/MAGNIMS research fellowship. DC, OC and FB are supported by the National Institute for Health Research biomedical research centre at University College London Hospitals. OC is an NIHR Research Professor (RP-2017–08-ST2–004). She also receives funding from MRC Research Grant (MR/S026088/1). This study was approved by our local ethics committee and the National Research Ethics Service (15/LO/0650). Participants gave informed consent, written if they attended in person, or verbal if they provided clinical information by telephone only. Funding Information: LH was supported by an ECTRIMS/MAGNIMS research fellowship. Funding Information: DC, OC and FB are supported by the National Institute for Health Research biomedical research centre at University College London Hospitals. Publisher Copyright: © 2023
PY - 2023/9/1
Y1 - 2023/9/1
N2 - Background: The relation of sarcopenia and disability in MS is unknown. Objective: To investigate the relation of temporal muscle thickness (TMT) and disability. Methods: A cohort of 132 people who presented with a clinically isolated syndrome (CIS) suggestive of MS at a mean age of 30.0 years, were prospectively followed clinically and with MRI over 30-years. TMT and expanded disability status scale (EDSS) were assessed at baseline, one- five- ten- fourteen- twenty- and thirty-year follow-up. Results: At 30-years, 27 participants remained classified as having had a CIS, 34 converted to relapsing remitting MS, 26 to secondary progressive MS, and 16 had died due to MS. Using linear mixed effect models with subject nested in time, greater annualized TMT-thinning was seen in individuals who developed MS (-0.04 mm/a, 95%CI: -0.07 to -0.01, p = 0.023). In those who converted to MS, a thinner TMT was reached at 14- (p = 0.008), 20- (p = 0.002) and 30-years (p< 0.001). TMT was negatively correlated with EDSS at 20-years (R=-0.18, p = 0.032) and 30-years (R-0.244, p = 0.005). Longitudinally, TMT at earlier timepoints was not predictive for 30-year clinical outcomes. Conclusion: TMT thinning is accelerated in MS and correlated with disability in later disease stages, but is not predictive of future disability.
AB - Background: The relation of sarcopenia and disability in MS is unknown. Objective: To investigate the relation of temporal muscle thickness (TMT) and disability. Methods: A cohort of 132 people who presented with a clinically isolated syndrome (CIS) suggestive of MS at a mean age of 30.0 years, were prospectively followed clinically and with MRI over 30-years. TMT and expanded disability status scale (EDSS) were assessed at baseline, one- five- ten- fourteen- twenty- and thirty-year follow-up. Results: At 30-years, 27 participants remained classified as having had a CIS, 34 converted to relapsing remitting MS, 26 to secondary progressive MS, and 16 had died due to MS. Using linear mixed effect models with subject nested in time, greater annualized TMT-thinning was seen in individuals who developed MS (-0.04 mm/a, 95%CI: -0.07 to -0.01, p = 0.023). In those who converted to MS, a thinner TMT was reached at 14- (p = 0.008), 20- (p = 0.002) and 30-years (p< 0.001). TMT was negatively correlated with EDSS at 20-years (R=-0.18, p = 0.032) and 30-years (R-0.244, p = 0.005). Longitudinally, TMT at earlier timepoints was not predictive for 30-year clinical outcomes. Conclusion: TMT thinning is accelerated in MS and correlated with disability in later disease stages, but is not predictive of future disability.
KW - Long-term outcome
KW - Multiple sclerosis
KW - Sarcopenia
KW - Temporal muscle thickness
UR - http://www.scopus.com/inward/record.url?scp=85164404684&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.msard.2023.104855
DO - https://doi.org/10.1016/j.msard.2023.104855
M3 - Article
C2 - 37442077
SN - 2211-0348
VL - 77
JO - Multiple Sclerosis and Related Disorders
JF - Multiple Sclerosis and Related Disorders
M1 - 104855
ER -